Gilead’s REMS Resubmission Delays FDA Action On Truvada For PrEP
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA extends the user fee deadline for the supplemental indication of HIV pre-exposure prophylaxis to Sept. 14. Although Gilead is not saying what changes it made to the Risk Evaluation and Mitigation Strategy, FDA advisory committee members had recommended making prescriber education mandatory and linking prescribing to documentation of a negative HIV test.